Status:
UNKNOWN
Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)
Lead Sponsor:
University Hospital, Bonn
Collaborating Sponsors:
Federal Ministry of Health, Germany
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in ...
Eligibility Criteria
Inclusion
- Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA
- Underwritten study consent
- No treatment with acetylcholinesterase inhibitors
- Mini-Mental-State Examination: 12-25 points
- Age: 50-80 Years
- Orale contraception for women of child-bearing age
Exclusion
- Mental Disorders
- Other Diseases of the CNS
- Severe Illness
- Contraindication for MRI-Scan
- Contraindication for Galantamin (Reminyl retard®)
- Participation at other clinical trials
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00637442
Start Date
February 1 2008
Last Update
November 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry, University Bonn
Bonn, Germany, 53127